BiotechTube
Excellos

Excellos

San Diego, United States· Est.
excellos.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Excellos is a specialized CDMO focused on supporting the development and manufacturing of adoptive cell therapies, including TIL, CAR-T/NK, and TCR therapies. Founded in 2015 as a spin-out from the San Diego Blood Bank, the company leverages over 70 years of tissue handling expertise and a proprietary deep characterization technology to provide high-quality, well-characterized starting materials and manufacturing services. Excellos partners with biotech companies from pre-clinical stages through commercialization, offering a full continuum of services to de-risk and accelerate cell therapy programs.

Oncology

Technology Platform

Excellos 360: A proprietary deep characterization platform that creates a comprehensive immune cell profile and assesses the metabolic and effector potential of donor cells, going beyond surface markers to reduce variability and improve clinical outcomes.

Opportunities

The rapid growth of the allogeneic (off-the-shelf) cell therapy market creates strong demand for characterized, banked donor cells and associated manufacturing services.
Increasing regulatory emphasis on understanding and controlling starting material variability positions Excellos's deep characterization platform as a key enabler for successful drug development and approval.

Risk Factors

Revenue is contingent on the success and progression of client programs, which are high-risk and subject to clinical failure or delay.
The company operates in an increasingly competitive CDMO landscape against larger, well-capitalized players and must continuously demonstrate superior technical execution and value.

Competitive Landscape

Excellos competes with large, diversified CDMOs (e.g., Lonza, Catalent, Thermo Fisher) and specialized cell therapy CDMOs (e.g., Oxford Biomedica Solutions, Cell Therapies Pty Ltd, ElevateBio). Its key differentiators are its integrated donor access via the San Diego Blood Bank and the proprietary Excellos 360 deep characterization technology, which focuses on reducing pre-manufacturing variability.

More companies in Cell & Gene Therapy →More companies in United States →